Literature DB >> 18377820

Combination versus sequential chemotherapy administration: is it time for a reevaluation of the issue?

Maurie Markman1.   

Abstract

Mesh：

Year:  2008        PMID： 18377820     DOI： 10.1007/s11912-008-0014-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  10 in total

1.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

Authors:  Andreas du Bois; Hans-Joachim Lück; Werner Meier; Hans-Peter Adams; Volker Möbus; Serban Costa; Thomas Bauknecht; Barbara Richter; Matthias Warm; Willibald Schröder; Sigrid Olbricht; Ulrike Nitz; Christian Jackisch; Günther Emons; Uwe Wagner; Walther Kuhn; Jacobus Pfisterer
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506

2.  Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

Authors:  Miriam Koopman; Ninja F Antonini; Joep Douma; Jaap Wals; Aafke H Honkoop; Frans Lg Erdkamp; Robert S de Jong; Cees J Rodenburg; Gerard Vreugdenhil; Olaf Jl Loosveld; Aart van Bochove; Harm Am Sinnige; Geert-Jan M Creemers; Margot Et Tesselaar; Peter H Th J Slee; Marjon Jbp Werter; Linda Mol; Otilia Dalesio; Cornelis Ja Punt
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

3.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Authors:  F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

4.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

Authors:  Jacobus Pfisterer; Marie Plante; Ignace Vergote; Andreas du Bois; Hal Hirte; Angel J Lacave; Uwe Wagner; Anne Stähle; Gavin Stuart; Rainer Kimmig; Sigrid Olbricht; Tien Le; Janusz Emerich; Walther Kuhn; James Bentley; Christian Jackisch; Hans-Joachim Lück; Justine Rochon; Annamaria Hayden Zimmermann; Elizabeth Eisenhauer
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

Review 5.  Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.

Authors:  Allan Covens; Mark Carey; Peter Bryson; Shailendra Verma; Michael Fung Kee Fung; Mary Johnston
Journal:  Gynecol Oncol       Date:  2002-04       Impact factor: 5.482

6.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

Authors:  J P Neijt; S A Engelholm; M K Tuxen; P G Sorensen; M Hansen; C Sessa; C A de Swart; F R Hirsch; B Lund; H C van Houwelingen
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

7.  Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

8.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

9.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

Authors:  M K B Parmar; J A Ledermann; N Colombo; A du Bois; J-F Delaloye; G B Kristensen; S Wheeler; A M Swart; W Qian; V Torri; I Floriani; G Jayson; A Lamont; C Tropé
Journal:  Lancet       Date:  2003-06-21       Impact factor: 79.321

10.  Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

Authors:  Sandro Pignata; Sabino De Placido; Rosalbino Biamonte; Giovanni Scambia; Giovanni Di Vagno; Giuseppe Colucci; Antonio Febbraro; Marco Marinaccio; Alessandra Vernaglia Lombardi; Luigi Manzione; Giacomo Cartenì; Mario Nardi; Saverio Danese; Maria Rosaria Valerio; Andrea de Matteis; Bruno Massidda; Giampietro Gasparini; Massimo Di Maio; Carmela Pisano; Francesco Perrone
Journal:  BMC Cancer       Date:  2006-01-07       Impact factor: 4.430
  10 in total
  1 in total

Review 1.  Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment.

Authors:  Emmanuel Mitry; Astrid Lièvre; Jean-Baptiste Bachet; Philippe Rougier
Journal:  Int J Colorectal Dis       Date:  2009-02-17       Impact factor: 2.571
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.